Summary
Recently there has been extensive development of orally active angiotensin converting enzyme (ACE) inhibitors in addition to those already marketed, for example, captopril, enalapril, lisinopril and ramipril. It was initially thought that ACE inhibitors were likely to be most useful as antihypertensive agents in conditions in which circulating renin and angiotensin II were elevated. However, it is now clear that they can also lower arterial pressure when plasma renin is not high. In addition, they have beneficial effects in cardiac failure.
Thus, captopril, enalapril, lisinopril and ramipril can be used in the treatment of mild to moderate hypertension either alone or in conjunction with diuretics or calcium antagonists. Broadly speaking, efficacy appears to be similar to that of β-blockers or diuretics. Unfortunately, however, there are no long term studies comparing one ACE inhibitor with another or with other classes of antihypertensive agents. Furthermore, there are no prognostic studies which show that use of ACE inhibitors reduces morbidity or mortality in hypertension.
Many new ACE inhibitors are undergoing clinical assessment, including alacepril, cilazapril, fosenopril, perindopril, quinapril and ramipril. The drugs vary, in that some exist in the active form whereas others are prodrugs which are converted to the active agent following absorption. In addition they each possess one of several ligands, for example, carboxyl, phosphinyl or sulfhydryl groups, and so vary in their affinity for ACE. Although many of these agents are renally excreted, a small number are metabolised via the liver (e.g. quinapril and spirapril) and this may prove advantageous in the presence of renal impairment.
In common with captopril and enalapril, the new ACE inhibitors inhibit the renin-angiotensin system and initial results suggest that they are effective in lowering blood pressure in essential hypertension. Furthermore, they reduce systemic vascular resistance in the absence of a reflex tachycardia.
There are a number of adverse effects which are attributable to the pharmacological mechanism of the ACE inhibitors as a group; these include hypotension, particularly in patients with high renin levels, prior diuretic use, renal impairment or in the elderly. Additional adverse effects may relate to chemical structure. The high incidence of adverse effects noted in early studies related to excess dosage and to the presence of a sulfhydryl group, which the more recently developed ACE inhibitors lack. The adverse effects most commonly reported with established and new ACE inhibitors include headache and fatigue, cough, skin rashes, hypotension and diarrhoea. As a group, ACE inhibitors have an acceptable but not negligible adverse effect burden. They need to be introduced cautiously if plasma renin is likely to be raised, and in the elderly, both circumstances in which first dose hypotension may occur. They can depress renal function in cases of bilateral renal artery stenosis and in cardiac failure.
The ACE inhibitors have now been shown to be effective in the treatment of moderate hypertension, in supporting the ailing heart, and in combination with various other classes of antihypertensive drugs. While caution is needed with any new type of agent until wide experience has accumulated, ACE inhibitors clearly possess several features which make them attractive candidates for the initiation of antihypertensive therapy.
Similar content being viewed by others
References
Ajayi AA, Elliott, HL, McCullough J, Hughes DM, Reid JL. Pharmacodynamics and dose response relationships of cilazapril in essential hypertension. British Journal of Clinical Pharmacology 21(1): 82P, 1986
Andren L, Karlberg BE, Svensson A, Ohman P, Nilsson OR, et al. Long term effects of captopril and atenolol in essential hypertension. Acta Medica Scandinavica 217: 155–160, 1985
Antonaccio MJ, Kerwin L. Pre- and post-junctional inhibition of vascular sympathetic function by captopril in SHR: implication of vascular angiotension II in hypertension and anti-hypertensive actions of captopril. Hypertension (Suppl. I): 154-162, 1981
Arr SM, Burgess J, Cooper WD. A comparative study of enalapril and atenolol in moderate to severe hypertension. British Journal of Clinical Pharmacology 18: 29P, 1984
Atkinson AB, Brown JJ, Cumming AMM, Fraser R, Lever AF, et al. Captopril in the management of hypertension with renal artery stenosis: its long-term effect as a predictor of surgical outcome. American Journal of Cardiology 49: 1460–1466, 1982
Atkinson AB, Brown JJ, Lever AF, Robertson JIS. Combined treatment of severe intractable hypertension with captopril and diuretic. Lancet 2: 105–107, 1980
Atkinson AB, Robertson JIS. Captopril in the treatment of clinical hypertension and cardiac failure. Lancet 2: 836–839, 1979
Atlas SA, Case DB, Yu ZY, Laragh JH. Hormonal and metabolic effects of angiotensin converting enzyme inhibitors: possible differences between enalapril and captopril. American Journal of Medicine 77(2A): 13–17, 1984
Ball SG. Age-related effects of converting enzyme inhibitors: a commentary. Journal of Cardiovascular Pharmacology 12 (Suppl. 8): S105–S108, 1988
Ball SG, Robertson JIS. A need for new converting enzyme inhibitors? British Medical Journal 290: 180–181, 1985
Blantz RC, Konner KS, Tucker BJ. Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat. Journal of Clinical Investigation 57: 419–434, 1976
Bolzano K, Arriaga J, Bemal R, Bernardes H, Calderon JL, et al. The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension. Journal of Cardiovascular Pharmacology 9 (Suppl. 3): S43–S47, 1987
Breckenridge A. Age-related effects of angiotensin converting enzyme inhibitors. Journal of Cardiovascular Pharmacology 12 (Suppl. 8): S100–S104, 1988
Brogden RN, Todd PA, Sorkin EM. Captopril: an update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in hypertension and congestive heart failure. Drugs 36: 540–600, 1988
Brouwer RML, Bolli P, Erne P, Corer D, Kiowski W, et al. Anti-hypertensive treatment using calcium antagonists in combination with captopril rather than diuretics. Journal of Cardiovascular Pharmacology 7 (Suppl.) S88–S91, 1985
Brown JJ, Davies DL, Lever AF, Parker RA, Robertson JIS. The assay of renin in single glomeruli in the normal rabbit and the appearance of the juxtaglomerular apparatus. Journal of Physiology 176: 418–428, 1965
Brown JJ, Davies DL, Parker PA, Lever AF, Robertson JIS. The assay of renin in single glomeruli and the appearance of the juxtaglomerular apparatus in the rabbit following renal artery constriction. Clinical Science 30: 223–235, 1966
Brown JJ, Leckie BJ, Lever AF, Mclntyre G, Morton JJ, et al. The renin-angiotensin system and the regulation of the circulation. In Robertson JIS (Ed.) Handbook of hypertension, Vol. 1: Clinical aspects of essential hypertension, pp. 278–323, Elsevier, Amsterdam, 1983
Buhler FR. Age and cardiovascular response adaptation: Determination of an antihypertensive treatment primarily based on beta-blockers and calcium entry blockers. Hypertension 5 (Suppl. 3): 94–100, 1983
Bussien JP, d’Amore TF, Perret L, Porchet M, Nussberger J, et al. Single and repeated dosing of the converting enzyme inhibitor perindopril to normal subjects. Clinical Pharmacology and Therapeutics 39(5): 554–558, 1986
Callender JS, Hodsman GP, Hutcheson MJ, Lever AF, Robertson JIS. Mood changes during captopril therapy for hypertension: a double-blind pilot study. Hypertension 5 (Suppl. 3): 90–93, 1983
Campbell DJ. The site of angiotensin production. Journal of Hypertension 3: 199–207, 1985
Captopril Research Group of Japan. Clinical effects of low-dose captopril plus a thiazide diuretic on mild to moderate essential hypertension: a multicenter double-blind comparison with propranolol. Journal of Cardiovascular Pharmacology 7 (Suppl. 1): S77–S81, 1985
Celentano A, Galderisi M, Mossetti G, Gerafulo M, Mureddu G. Ketanserin in elderly hypertension: comparison and combination with enalapril. Abstracts. International Symposium on Serotonin, Florence, p80, 1989
Chakraborty TK, Ruddell WSJ. Guillain-Barre neuropathy during treatment with captopril. Postgraduate Medical Journal 63: 221–222, 1987
Chalmers D, Dombey SL, Lawson DH. Postmarketing surveillance of captopril (for hypertension): a preliminary report. British Journal of Clinical Pharmacology 24: 343–350, 1987
Chinn RH, Dusterdieck G. The response of blood pressure to infusion of angiotensin II: relation to plasma concentrations of renin and angiotensin II. Clinical Science 42: 489–504, 1972
Chrysant SG, Brown RD, Kern DC, Brown JL. Antihypertensive and metabolic effects of a new converting enzyme inhibitor, enalapril. Clinical Pharmacology and Therapeutics 33: 741–746, 1983
Cleland JGF, Dargie HJ, Ball SG, Gillen G, Hodsman GP, et al. Effects of enalapril in heart failure: a double-blind study on exercise performance, renal function, hormones and metabolic state. British Heart Journal 54: 305–312, 1985b
Cleland JGF, Dargie HJ, Hodsman GP, Ball SG, Robertson JIS. Captopril in heart failure: a double blind controlled trial. British Heart Journal 52: 530–535, 1984
Cleland JG, Dargie HJ, McAlpine H, Ball SG, Morton JJ, et al. Severe hypotension after first dose of enalapril in heart failure. British Medical Journal 291: 1309–1312, 1985a
Cooper WD, Sheldon D, Brown D, Kimber GP, Isitt V, et al. Postmarketing surveillance of enalapril: experience of 11710 hypertensive patients in general practice. Journal of the Royal College of General Practitioners 37: 346–349, 1987
Costa FV, Borghi C, Boschi S, Ambrosiani E. Differing dosages of captopril and hydrochlorothiazide in the treatment of hypertension: long-term effects on metabolic values and intracellular electrolytes. Journal of Cardiovascular Pharmacology 7 (Suppl. 1): S70–S76, 1985
Costa FV, Montebugnoli L, Tartagni F, Ambrosiani E, Magnani B. Increased intra-lymphocytic sodium content in essential hypertension: an index of impaired Na cellular metabolism. Clinical Science 61: 21S–23S, 1981
Coulter DM, Edwards IR. Cough associated with captopril and enalapril. British Medical Journal 294: 1521–1523, 1987
Creisson C, Baulac L, Lenfant B. Captopril/hydrochlorothiazide combination in elderly patients with mild to moderate hypertension. Postgraduate Medical Journal 62: 139–141, 1986
Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, et al. The effects of antihypertensive therapy on the quality of life. New England Journal of Medicine 314(26): 1657–1664, 1986
Daly P, Mettauer B, Rouleau JL, Cousineau D, Burgess JH. Lack of reflex increase in myocardial sympathetic tone after captopril: potential antianginal effect. Circulation 71: 317–325, 1985
Davies RO, Irvin JD, Kramsch DK, Walker JF, Moncloa F. Enalapril worldwide experience. American Journal of Medicine 77(2A): 23–25, 1984
DeFelice EA, Kostis JB. New ACE inhibitors. In Kostis JB & DeFelice EA (Eds) Angiotensin converting enzyme inhibitors, pp. 213–261, Alan R. Liss Inc, New York, 1987
de Leeuw PW, Birkenhager WH. Short and long-term effects of ramipril in hypertension. American Journal of Cardiology 59: 79D-82D, 1987
Dickinson CJ, Lawrence JR. A slowly developing pressor response to small concentrations of angiotensin; its bearing on the pathogenesis of chronic renal hypertension. Lancet 1: 1354–1356, 1963
Doi Y, Atarashi K, Franco-Saenz R, Mulrow P. Adrenal renin: a possible regulator of aldosterone production. Clinical and Experimental Hypertension (A) 5(7-8): 1119–1126, 1983
Duchin K, Tu J, Frantz M, Willard D. Pharmacodynamics and pharmacokinetics of SQ-28.555, a new angiotensin-converting enzyme (ACE) inhibitor, in healthy subjects. Clinical Pharmacology and Therapeutics 37: 192, 1985
Dunn FG, Oigman W, Ventura HO, Messerli FM, Kobrin I, et al. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. American Journal of Cardiology 53: 105–108, 1984
Dzau VJ. Implications of local angiotensin production in cardiovascular physiology and pharmacology. American Journal of Cardiology 59: 59A-65A, 1987
Dzau VJ (Ed.). Tissue renin-angiotensin system: physiologic and pharmacologic implications. Circulation 77 (Suppl. I), 1988
Dzau VJ, Colucci WS, Williams GH, Curfman G, Meggs L, et al. Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. New England Journal of Medicine 302: 1373–1379, 1980
Editorial. Captopril: benefits and risks in severe hypertension. Lancet 2: 409–452, 1980
Editorial. Treatment of hypertension in the over-60s. Lancet 1: 1369–1370, 1985
Edwards CRW, Padfield PL. Angiotensin converting enzyme inhibitors: past, present and bright future. Lancet 1: 30–34, 1985
Fagard R, Bulpitt C, Lijner P, Amery A. Response of the systemic and pulmonary circulation to converting-enzyme inhibition (captopril) at rest and during exercise in hypertensive patients. Circulation 65: 33–39, 1982
Felder K, Witte PU. Effects of the new oral angiotensin converting enzyme inhibitor HOE-498 in essential hypertension. Arzneimittel Forschung 34: 1452–1454, 1984
Ferreira SH, Bartelt DC, Greene LJ. Isolation of bradykinin-potentiating peptides from Bothrups jararaca venom. Biochemistry 9: 2583–2593, 1970
Foley J, Taafe B, Buick I, Darragh A. A noninvasive method to assess the pharmacodynamics (PD) of angiotensin-converting enzyme (ACE) inhibitors (CEI). Clinical Pharmacology and Therapeutics 37: 196, 1985
Fouad-Tarazi FM. Structural cardiac and vascular changes in hypertension: response to treatment. Current Opinion in Cardiology 2: 782–786, 1987
Francis RJ, Brown AN, Kler L, Fasanella d’Amore T, Nussberger J, et al. Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model. Journal of Cardiovascular Pharmacology 9: 32–38, 1987
Freeman RH, Davis JO. Factors controlling renin secretion and metabolism. In Genest J et al. (Eds) Hypertension: patho-physiology and treatment, 2nd ed. pp. 225–250, McGraw-Hill Book Company, New York, 1983
Frohlich ED, Cooper RA, Lewis EJ. Review of the overall experience of captopril in hypertension. Archives of Internal Medicine 144: 1441–1444, 1984
Ganten D, Lang RE, Lehmann E, Unger TM. Brain angiotensin: on the way to becoming a well-studied neuropeptide system. Biochemical Pharmacology 33: 3523–3528, 1984
Garinin G. A comparison of once-daily antihypertensive therapy with captopril and enalapril. Current Therapeutic Research 40: 567–575, 1986
Gavras H, Gavras I. Angiotensin converting enzyme inhibitors: properties and side effects. Hypertension 11 (Suppl. II) II37–1141, 1988
Gavras I. Pilot study of the effects of the angiotensin converting enzyme inhibitor CI-906 on patients with essential hypertension. Journal of Clinical Pharmacology 24: 343–350, 1984
Gavras I, Gavras H. The use of ACE inhibitors in hypertension. In Kostis JB & De Felice EA (Eds) Angiotensin converting enzyme inhibitors, pp. 93–122, Alan R. Liss Inc., New York, 1987
Gomez HJ, Salonen J, Salonen R, Rissanen V, Cirillo VJ et al. Lisinopril: dose-peak effect relationship. Clinical Pharmacology and Therapeutics 41: 187, 1987
Gomez HJ, Sromovsky MS, Kristianson K, Cirillo VJ, Wilhelmsson CE, et al. Lisinopril dose response in mild to moderate hypertension. Clinical Pharmacology and Therapeutics 37(2): 198, 1985
Goodwin FJ. A comparative study of enalapril and propranolol in mild to moderate essential hypertension. Abstract no. L-17. Symposium on the Management of Congestive Heart Failure and Hypertension, London, 1984
Gross DM, Sweet CS, Ulm EH, Backlund EP, Morris AA, et al. Antihypertensive activity of N-[(S)]-l-(ethoxycarbonyl)]-3-phenylpropyl-L-Ala-L-Pro and its ethyl ester (MK-42a) on angiotensin-converting enzyme in vitro and angiotensin I pressor responses in vivo. Journal of Pharmacology and Experimental Therapeutics 216: 552–557, 1981
Grossman A, Eckland D, Price P, Edwards CRW. Captopril: reversible renal failure with severe hyperkalaemia. Lancet 1:712, 1980
Haber E. Renin inhibitors. New England Journal of Medicine 311: 1631–1633, 1984
Hackenthal E, Metz R, Buhrle CP, Taugner R. Intra renal and intra cellular distribution of renin and angiotensin. Kidney International 31 (Suppl. 20): S4–S17, 1987
Hall J, Guyton A, Jackson T, Coleman T, Lohmeier T, et al. Control of glomerular filtration rate by the renin-angiotensin system. American Journal of Physiology 223: F366–F372, 1977
Harris PJ, Navar LG. Tubular transport responses to angiotensin. American Journal of Physiology 248: F621–F630, 1985
Harris PJ, Young JA. Dose-dependent stimulation and inhibition of proximal tubular sodium reabsorption by angiotensin II in the rat kidney. Pflugers Archives 367: 295–297, 1977
Havelka J, Vetter H, Studer A, Greminger P, Luscher T, et al. Acute and chronic effects of the angiotensin-converting enzyme inhibitor captopril in severe hypertension. American Journal of Cardiology 49: 1467–1474, 1982
Heel RC, Brogden RN, Speight TM, Avery GS. Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 20: 409–458, 1980
Helgeland A, Hagelind CH, Strommen R, Tretli S. Enalapril, atenolol and hydrochlorothiazide in mild to moderate hypertension. Lancet 1: 872–875, 1986
Herrera-Acosta J, Perez-Grovas H, Fernandez M, Arriaga J. Enalapril in essential hypertension. Drugs 30 (Suppl. 1): 35–46, 1985
Hodsman GP, Brown JJ, Cumming AMM, Davies DL, East BW, et al. Enalapril (MK 421) in the treatment of hypertension with renal artery stenosis: changes in blood pressure, renin, angiotensin I and II, renal function and body composition. American Journal of Medicine 77(2A): 52–60, 1984
Hodsman GP, Brown JJ, Davies DL, Fraser R, Lever AF, et al. Converting-enzyme inhibitor, enalapril (MK421) in treatment of hypertension with renal artery stenosis. British Medical Journal 285: 1697–1699, 1983a
Hodsman GP, Isles CG, Murray GD, Usherwood TP, Webb DJ, et al. Factors related to the first dose hypotensive effect of captopril: prediction and treatment. British Medical Journal 286: 832–834, 1983b
Hollenberg NK. Angiotensin-converting enzyme inhibition: renal aspect. Journal of Cardiovascular Pharmacology 7 (Suppl. I): S40–S44, 1985
Hommel E, Parving H-H, Mathiesen E, Edsberg B, Damjaer-Nielsen M, et al. Effect of captopril on kidney function in insulin-dependent diabetic patients with nephropathy. British Medical Journal 293: 467–470, 1986
Hostetter TH, Rennke HG, Brenner BM. The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies. American Journal of Medicine 72: 375–380, 1982
Ibsen H, Egan B, Osterziel K, Vander A, Julius S. Reflux-hemodynamic adjustments and baroreceptor reflux sensitivity during converting enzyme inhibition with MK 421 in normal humans. Hypertension 5 (Suppl. 1): 1184–1191, 1983
Ichikawa I, Miele JF, Brenner BM. Reversal of renal cortical actions of angiotensin II by verapamil and manganese. Kidney International 16: 137–147, 1979
Inman WHW, Rawson NSB, Wilton LV, Pearce GL, Spiers CJ. Postmarketing surveillance of enalapril. I. Results of prescription-event monitoring. British Medical Journal 297: 826–929, 1988
Johnstone GD (Ed.). First international symposium on cilazopril: preclinical and clinical pharmacology. British Journal of Clinical Pharmacology 27 (Suppl. 2), 1989
Karlberg BE, Fyhrquist F, Gronhagen-Risha C, Tikkanen I, Ohman KP. Enalapril and lisinopril in renovascular hypertension: antihypertensive and hormonal effects of two new angiotensin-converting enzyme (ACE) inhibitors: a preliminary report. Scandinavian Journal of Urology and Nephrology 79 (Suppl.): 103–104, 1984
Karlberg BE, Lindstrom T, Rosenqvist R, Ohman KP. Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498) in mild to moderate primary hypertension. American Journal of Cardiology 59: 104D-109D, 1987
Keeton TK, Campbell WB. The pharmacological alteration of renin release. Pharmacology Review 32: 81–227, 1981
Kelleher CC. ACE inhibitors in the prevention and therapy of diabetic nephropathy: what is their role? Drugs 39: 639–645, 1990
Kohlmann O, Breshnahan M, Gavras H. Central and peripheral indices of sympathetic activity after blood pressure lowering with enalapril (MK-421) or hydralazine in normotensive rats. Hypertension 6 (Suppl. 1) 11–16, 1984
Lancaster SG, Todd PA. Lisinopril: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 35: 646–669, 1988
Laragh J. Atrial natriuretic hormone, the renin aldosterone axis, and blood pressure-electrolyte homeostasis. New England Journal of Medicine 33: 1330–1340, 1985
Lederle RM. Captopril and hydrochlorothiazide in the fixed combination multicenter trial. Journal of Cardiovascular Pharmacology 7 (Suppl. 1): S63–S69, 1985
Ledingham JGG (Ed.). Angiotensin, ACE inhibition and the kidney. Kidney International 31 (Suppl. 20), 1987
Lees KR, Reid JL. Single and multiple administration of an angiotensin converting enzyme inhibitor, S-9490-3, in normotensive subjects. British Journal of Clinical Pharmacology 19(1): 132–133P, 1985
Lewis RA, Baker KM, Ayers CR, Weaver BA, Lehmann MR. Captopril versus enalapril maleate: a comparison of antihypertensive and hormonal effects. Journal of Cardiovascular Pharmacology 7 (Suppl. 1): S12–S15, 1985
Lichter I, Richardson PJ, Wyke MA. Differential effects of antenolol and enalapril on tests of memory during treatment for essential hypertension. Journal of Hypertension 2: 560, 1984
Lin S-Y, Goodfriend TL. Angiotensin receptors. American Journal of Physiology 218: 1319–1328, 1970
Lund-Johansen O. Long-term haemodynamic effects of enalapril (alone and in combination with hydrochlorothiazide) at rest and during exercise in essential hypertension. Journal of Hypertension 2 (Suppl. 2): 29–56, 1984
Lund-Johansen P, Omvik P. Long-term haemodynamic effects of enalapril alone and in combination with hydrochlorothiazide at rest and during exercise in essential hypertension. Journal of Hypertension 2 (Suppl. 2): 49–56, 1984
MacGregor GA, Markandu ND, Banks RA, Bayliss J, Roulston JE, et al. Captopril in essential hypertension; contrasting effects of adding hydrochlorothiazide or propanolol. British Medical Journal 284: 693–696, 1982
MacGregor GA, Markandu ND, Bayliss J, Roulston J, Squires M, et al. Non-sulphydryl containing converting-enzyme inhibitor (MK 421): evidence for role of renin system in normotensive subjects. British Medical Journal 283: 401–403, 1981
MacGregor GA, Markandu ND, Smith SJ, Sagnella G A. Captopril: contrasting effects of adding hydrothiazide, propranolol or nifedipine. Journal of Cardiovascular Pharmacology 7 (Suppl.) S82–S87, 1985
Marre M, Leblanc H, Suarez L, Guyenne T-T, Menard J, et al. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria. British Medical Journal 294: 1448–1452, 1987
Matsuno Y, Taira N, Fujitani B, Ito T, Kadokawa T. General pharmacology of the novel angiotensin converting enzyme inhibitor, alacepril. Arzneimittel-Forschung 36: 55–62, 1986
McAreavey D, Ramsay LE, Lathan L, McLaren AD, Lorimer AR, et al. Third drug trial: comparative study of antihypertensive agents added when blood pressure remains uncontrolled by betablocker plus diuretic. British Medical Journal 288: 106–111, 1984
McFate Smith W, Kulaga SF, Moncloa F, Pingeon R, Walker JF. Overall tolerance and safety of enalapril. Journal of Hypertension 2 (Suppl. 2): 113–117, 1984
Medical Research Council. Adverse reactions to bendrofluazide and propanolol following treatment of mild hypertension. Lancet 2: 539–543, 1981
Medical Research Council. Ventricular extrasystoles during thiazide treatmerit. British Medical Journal 287: 1249–1253, 1983
Menard J, Alhenc-Gelas F, Gardes J, Misumi J, Corvol P. Intrarenal formation of and role of angiotensins: practical implications. In Doyle AE & Beam AG (Eds) Hypertension and the angiotensin system: therapeutic approaches, pp. 109–121, Raven Press, New York, 1984
Mendelsohn FAO, Millan M, Quirion R, Aguilera G, Chou ST, et al. Localization of angiotensin II receptors in rat and monkey kidney by in vitro autoradiography. Kidney International 30 (Suppl. 20): 40–44, 1987
Merrill DD, Byyny RL, Carr A, Dauer AD, Kazilionis JE, et al. Lisinopril/hydrochlorothiazide in essential hypertension. Clinical Pharmacology and Therapeutics 41: 227, 1987
Mezzetti A, Guglielmi MD, Ciampi P, Botta G, Porreca E, et al. Effects of chronic captopril therapy on blood pressure and left ventricular response to exercise in mild to moderate hypertension with and without cardiac hypertrophy. Current Therapeutic Research 42: 286–296, 1987
Mimran A, Ribstein J. Effect of chronic nifedipine in patients inadequately controlled by a converting enzyme inhibitor and a diuretic. Journal of Cardiovascular Pharmacology 7 (Suppl.) S92–S95, 1985
Mirkin BL, Newman TJ. Efficacy and safety of captopril in the treatment of severe childhood hypertension: report of the International Collaborative Study Group. Pediatrics 75(6): 1091–1100, 1985
Morgan T, Anderson A. Interaction of slow-channel calcium blocking drugs with sodium restriction, diuretics and angiotensin converting enzyme inhibitors. Journal of Hypertension 6 (Suppl. 4): S652–S654, 1988
Morgan T, Anderson A, Wilson D, Murphy J, Nowson C. The effect of perindopril on blood pressure in humans on different sodium intakes. Journal of Cardiovascular Pharmacology 10 (Suppl. 7): S119–S121, 1987
Morganti A, Sala C, Turolo L, Palermo A, Zanchetti A. Participation of the renin-angiotensin system in the maintenance of blood pressure during changes in posture in patients with essential hypertension. Journal of Hypertension 3: 55–61, 1985
Morlin C, Baglivo H, Boeijinga JK, Breckinridge AM, Clement D, et al. Comparative trial of lisinopril and nifedipine in mild to severe essential hypertension. Journal of Cardiovascular Pharmacology 9 (Suppl. 30): S48–S52, 1987
Naruse M, Takii Y, Inagami T. Renin exists in high concentrations in the adrenal gland of the rat. Biomedical Review 2: 583, 1981
Navar LG, Carmines PK, Huang W-C, Mitchell KC. The tubular effects of angiotensin II. Kidney International 31 (Suppl. 20): S81–S89, 1987
Nelson EB, Chrysant SG, Gradman AH, Leon AS, McCarthy P, et al. Dose response of lisinopril efficacy in hypertension. Journal of Clinical Pharmacology 25: 455–474, 1985
Onoyama K, Hirahata H, Tsuruda H, Ohchi N, Tomooka S, et al. Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states. Clinical Pharmacology and Therapeutics 38: 462–468, 1985
Onoyama K, Kumagai H, Narishi F, et al. Pharmacokinetic properties of a new angiotensin I converting enzyme inhibitor, alacepril, in normal office workers. Current Therapeutic Research 40: 543–550, 1986
Parving H-H, Hommel E, Nielsen MD, Giese J. Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy. British Medical Journal 299: 533–536, 1989
Patchett AA, Harris E, Tristam EW, Wyvratt MJ, Wu MJ, et al. A new class of angiotensin-converting enzyme inhibitors. Nature 288: 280–283, 1980
Peach MJ. Renin-angiotensin system: biochemistry and mechanisms of action. Physiological Reviews 57: 313–370, 1977
Peart WS. Renin release. General Pharmacology 9: 65–72, 1978
Perez-Stable E, Caralis PV. Thiazide-induced disturbances in carbohydrate, lipid and potassium metabolism. American Heart Journal 106: 245–251, 1983
Petrillo EW, Ondetti MA. Angiotensin-converting enzyme inhibitors: medicinal chemistry and biological actions. Medical Research Reviews 2(1): 1–41, 1982
Phillips MA. New evidence for brain angiotensin and for its role in hypertension. Federation Proceedings 42: 2667–2672, 1983
Pool JL, Gennari J, Goldstein R, Kochar MS, Lewin AJ, et al. Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide and lisinopril plus hydrochloro-thiazide in the treatment of 394 patients with mild to moderate essential hypertension. Journal of Cardiovascular Pharmacology 9 (Suppl. 3): S36–S42, 1987
Potter JF, Beevers GB. Comparison of nifedipine and captopril as third-line agents in hypertensive patients uncontrolled with betablocker and diuretic therapy. Journal of Clinical Pharmacology 27: 410–414, 1987
Predel HG, Dusing R, Backer A, Kipnowski J, Kramer HJ. Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril. American Journal of Cardiology 59: 143D-148D, 1987
Raine AEG, Ledingham JGG. Clinical experience with captopril in the treatment of severe drug-resistant hypertension. American Journal of Cardiology 49: 1475–1479, 1982
Rakhit A, Hurley ME, Tipuis V, Coleman J, Rommel A, et al. Pharmacokinetics and pharmacodynamics of pentopril, a new angiotensin-converting enzyme inhibitor in humans. Journal of Clinical Pharmacology 26: 156–164, 1986
Re R, Rovigatti U. New approaches to the study of the cellular biology of the cardiovascular system. Circulation 77 (Suppl. I): 114–117, 1988
Reid IA. Actions of angiotensin II on the brain: mechanisms and physiological role. American Journal of Physiology 246: F533–F543, 1984
Reid IA. The renin-angiotensin system and body function. Archives of Internal Medicine 145: 1475–1479, 1985
Reid JL. Angiotensin converting enzyme inhibitors in the elderly. British Medical Journal 295: 943–944, 1987
Richards AM, Tonolo G, Tree M, Robertson JIS, Montorei P, et al. Atrial natriuretic peptides and renin release. American Journal of Medicine 84: 112–118, 1988
Richer C, Dousau M-P, Giudicelli J-F. Systemic and regional hemodynamic profile of five angiotensin I converting enzyme inhibitors in the spontaneously hypertensive rat. American Journal of Cardiology 59: 12D-17D, 1987
Robertson JIS (Ed.). The renin-angiotensin system, Gower Press, London, 1984
Robertson JIS. The large studies in hypertension; what have they shown? British Journal of Clinical Pharmacology 24 (Suppl): 3–14, 1987
Robertson JIS. Hypertension and its treatment in the elderly. Clinical and Experimental Hypertension, in press, 1989
Robertson JIS, Doyle AE, Vanhoutte PM (Eds). Age-related effects of antihypertensive therapy. Journal of Cardiovascular Pharmacology 12 (Suppl. 8): 1–182, 1988
Robertson JIS, Tillman DM, Ball SG, Lever AF. Angiotensin converting enzyme inhibition in hypertension. Journal of Hypertension 5 (Suppl. 3): S19–S25, 1987
Robinson BJ, Johnson RH, Lambie DG, Palmer KT. Do elderly patients with an excessive fall in blood pressure on standing have evidence of autonomie failure? Clinical Science 46: 587–589, 1983
Rotmensch HH, Vlasses PH, Swanson BN, Irvin JD, Harris KE, et al. Antihypertensive efficacy of once daily MK-521, a new nonsulfhydryl angiotensin-converting enzyme inhibitor. American Journal of Cardiology 53(1): 116–119, 1984
Rotmensch HM, Vlasses PH, Swanson BN, Mojaverian P, Ferguson RK. Captopril and enalapril: comparative blood pressure and humoral responses in hypertensive patients. Clinical Research 30: 217A, 1982
Rumboldt Z, Marinkovic M, Drinovic J. Enalapril versus captopril: a double-blind multicentre comparison in essential hypertension. International Journal of Clinical Pharmacology Research 8: 181–188, 1988
Rush JE, Merrill DD. The safety and tolerability of lisinopril in clinical trials. Journal of Cardiovascular Pharmacology 9 (Suppl. 3) S99–S107, 1987
Ryan MP, Ryan MF, Counihan TB. The effects of diuretics on lymphocyte magnesium and potassium. Acta Medica Scandinavica 209: 153–161, 1981
Salvetti A. Ketanserin interactions with other antihypertensive drugs: Italian crossover trials. Abstracts, International Symposium on Serotonin, Florence, p75, 1989
Sassano P, Chatellier G, Alhenc-Gelas F, Corvol P, Menard J, Antihypertensive effect of enalapril as first-step treatment of mild and moderate uncomplicated essential hypertension. American Journal of Medicine 77: 18–22, 1984a
Sassano P, Chatellier G, Amiot A-M, Alhenc-Gelas F, Corvol P, et al. A double-blind randomized evaluation of converting enzyme inhibition as the first treatment of mild to moderate hypertension. Journal of Hypertension 2 (Suppl. 2): 75–80, 1984
Schaller MD, Waeber B, Nussberger J, Brunner HR. Initial evaluation of the angiotensin converting enzyme inhibitor CGS 13945 in hypertensive patients. Current Therapeutic Research 37: 843–852, 1985
Scroop GC, Lowe RD. Efferent pathways of the cardiovascular response to vertebral artery infusions of angiotensin in the dog. Clinical Science 37: 605, 1969
Simon AC, Levenson JA, Boulthien J, Maarek B, Safar ME. Effects of acute and chronic angiotensin converting enzyme inhibition on large arteries in human hypertension. Journal of Cardiovascular Pharmacology 7 (Suppl. 1): S45–S55, 1985
Singer DR, Markandu ND, Shore AC, MacGregor G A. Captopril and nifedipine in combination for moderate-to-severe hypertension. Hypertension 9: 629–633, 1987
Singhvi SM, Duchin KL, Morrison RA, Willard DA, Everett DW, et al. Disposition of fosinopril sodium in healthy subjects. British Journal of Clinical Pharmacology 25: 9–15, 1988
Skeggs LT, Lentz KE, Gould AB, Hochstrasser H, Kahn JR. Biochemistry and kinetics of the renin-angiotensin system. Federation Proceedings 26: 42–47, 1967
Solomon TA, Caruso FS, Vukovich RA. Hemodynamic and hormonal changes in hypertensive patients after inhibition of angiotensin converting enzyme (ACE) by pivalopril. Clinical Pharmacology and Therapeutics 33(2): 231, 1983
Speirs CJ, Dollery CT, Inman WHW, Rawson NSB, Wilton LV. Postmarketing surveillance of enalapril. II. Investigation of the potential role of enalapril in deaths with renal failure. British Medical Journal 297: 830–832, 1988
Staessen J, Fagard R, Lijnen P, Verschueren LJ, Amery A. The hypotensive effect of propranolol in captopril-treated patients does not involve the plasma renin-angiotensin-aldosterone system. Clinical Science 61: 441S-444S, 1981
Staessen J, Fagard R, Lijnen P, Verschueren LJ, Amery A. Double-blind comparison between propranolol and bendroflumethiazide in captopril-treated resistant hypertensive patients. American Heart Journal 106: 321–328, 1983
Staessen J, Fagard R, van Hoof R. Amery A. Antihypertensive drug treatment in elderly hypertensive subjects; evidence of protection. Journal of Cardiovascular Pharmacology 12 (Suppl. 8): S33–S38, 1988
Stokes GS, Edwards KDG (Eds). Drugs affecting the renin-angiotensin-aldosterone system: use of angiotensin inhibitors. Progress in Biochemical Pharmacology, Vol. 12, Karger, Basel, 1975
Studdy PR, Lapworth R, Bird R. Angiotensin-converting enzyme and its clinical significance: a review. Journal of Clinical Pathology 36: 938–947, 1983
Stumpe KO, Kolloch R, Overlack A. Captopril and enalapril: evaluation of therapeutic efficacy and safety. Practical Cardiology 10(7): 111–124, 1984
Swales JD, Ramsay LE, Coope JR, Pocock SJ, Robertson JIS, et al. Treating mild hypertension: report of the British Hypertension Society working party. British Medical Journal 298: 694–699, 1989
Swartz SL, Williams GH. Angiotensin-converting enzyme inhibition and prostaglandins. American Journal of Cardiology 49: 1404–1409, 1982
Sybertz EJ, Watkins FJ, Ahn HS, Baum T, La Rocca P, et al. Pharmacologic, metabolic and toxicologic profile of spirapril (SCH 33844), a new angiotensin converting inhibitor. Journal of Cardiovascular Pharmacology 10 (Suppl. 7): S105–S109, 1987
Taguma Y, Kitamoto Y, Futaki G, Veda H, Monma H, et al. Effect of captopril on heavy proteinuria in azotemic diabetics. New England Journal of Medicine 313: 1617–1620, 1985
Thind GS, Johnson A, Bhatnagar D, Herkel TW. A parallel study of enalapril and captopril and one year of experience with enalapril treatment in moderate-to-severe hypertension. American Heart Journal 109: 852–858, 1985
Tigerstedt RR, Bergman PG. Niere und Kreislauf. Scandinavian Archives of Physiology 8: 223–271, 1898
Tillman DM, Adams FG, Gillen G, Morton JJ, Robertson JIS. Ramipril for hypertension secondary to renal artery stenosis: changes in blood pressure, the renin-angiotensin system and total and divided renal function. American Journal of Cardiology 59(10): 133D–142D, 1987
Todd PA, Heel RC. Enalapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure. Drugs 31: 198–248, 1986
Tuck ML, Katz LA, Kirkendall WM, Koeppe PR, Ruoff GF, et al. Low dose captopril in mild to moderate geriatric hypertension. Journal of the American Geriatrics Society 34: 693–696, 1986
van Schaik AM, Geyskes GG, Ross JC, Korhout Mees EJ. Changes in blood pressure and body fluid volumes during diuretic therapy in patients with essential hypertension who receive enalapril. Clinical Pharmacology and Therapeutics 39: 60–64, 1986
Veterans Administration Cooperative Study Group on Anti-hypertensive Agents. Captopril: evaluation of low doses, twice-daily doses, and the addition of diuretic for the treatment of mild to moderate hypertension. Clinical Science 63 (Suppl. 8): 443S–445S, 1982a
Veterans Administration Cooperative Study Group on Anti-hypertensive Agents. Racial differences in response to low-dose captopril abolished by the addition of hydrochlorothiazide. British Journal of Clinical Pharmacology 14 (Suppl. 2): 97A–101S, 1982b
Veterans Administration Cooperative Study Group on Anti-hypertensive Agents. Low-dose captopril for the treatment of mild to moderate hypertension. Archives of Internal Medicine 144: 1947–1953, 1984
Vidt DG, for the Multiclinic Study Group. A controlled multi-clinic study to compare the antihypertensive effects of MK-421, hydrochlorothiazide, and MK-421 combined with hydrochlorothiazide in patients with mild to moderate essential hypertension. Journal of Hypertension 2 (Suppl. 2): 81–88, 1984
Villamil AS, Cairns V, Witte PU, Bertolasi C. A double-blind study to compare the efficacy, tolerance and safety of two doses of the angiotensin converting enzyme inhibitor ramipril with placebo. American Journal of Cardiology 59: 110D–114D, 1987
Vlasses PH, Rotmensch HH, Swanson BN, Irvin JD, Lee RB, et al. Comparative antihypertensive effects of enalapril maleate and hydrochlorothiazide alone and in combination. Journal of Clinical Pharmacology 23: 227–233, 1983
Vlasses PH, Rotmensch HH, Swanson BN, Mojaverian P, Ferguson RK. Low-dose captopril: its use in mild to moderate hypertension unresponsive to diuretic treatment. Archives of Internal Medicine 142: 1098–1101, 1982
Webb DJ, Collier JG. Influence of ramipril diacid on the peripheral vascular effects of angiotensin I. American Journal of Cardiology 59: 45D-49D, 1987
Webb DJ, Manhem PJO, Ball SG, Inglis G, Leckie BJ. Study of the renin inhibitor H142 in man. Journal of Hypertension 3: 653–658, 1985
Weber MA, et al. Spirapril: pharmacology and clinical efficacy of a new, long-acting, non-sulfhydryl ACE inhibitor. Presented at the Scientific Meeting of the International Society of Hypertension, Heidelberg, West Germany, Aug 31-Sep 7, 1986
Webster J, Petrie JC, Robb OJ, Trafford J, Burgess J. Enalapril in moderate to severe hypertension: a comparison with atenolol. British Journal of Clinical Pharmacology 21: 489–495, 1986
Weinberger MH. Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients. Journal of Cardiovascular Pharmacology 7 (Suppl. 1): S52–S55, 1985
Weinberger MH. Metabolic and blood pressure effects of converting enzyme inhibitors in mild-to-moderate American hypertensives. Clinical and Experimental Hypertension 9: 643–652, 1987
Wenting GJ, Tan-Tjiong HL, Derkx FHM, de Bruyn JHB, Man in’t Veld AJ, et al. Split renal function after captopril in unilateral renal artery stenosis. British Medical Journal 288: 886–890, 1984
White WB, Viadero JJ, Lane TJ, Podesla S. Effect of combination therapy with captopril and nifedipine in severe or resistant hypertension. Clinical Pharmacology and Therapeutics 39: 43–48, 1986
Williams GH. Converting-enzyme inhibitors in the treatment of hypertension. New England Journal of Medicine 319: 1517–1525, 1988
Wing LMH, Chalmers JP, West MJ, Russell AE, Morris MJ, et al. Enalapril and atenolol in essential hypertension: attenuation of hypotensive effect in combination. Clinical and Experimental Hypertension 10: 119–133, 1988
Witte PU, Walter U. Comparative double-blind study of ramipril and captopril in mild to moderate essential hypertension. American Journal of Cardiology 59: 115D-120D, 1987
Woods RL, Anderson WP, Korner P. Renal and systemic effects of continuous enalapril treatment in chronic one-kidney Gold-blatt hypertension. Hypertension 8: 109–116, 1986
Wyvratt MJ, Patchett AA. Recent developments in the design of angiotensin-converting enzyme inhibitors. Medical Research Reviews 5(4): 483–531, 1985
Zachariah PK, Bonnet G, Chrysant SG, DeBackeria G, Goldsteinia R, et al. Evaluation of the antihypertensive efficacy of lisinopril compared to metoprolol in moderate to severe hypertension. Journal of Cardiovascular Pharmacology 9 (Suppl. 3): S53–S58, 1987
Zanchetti A, Tarazi RC (Eds). Symposium on angiotensin-converting enzyme inhibition: a developing concept. American Journal of Cardiology 49: 1381–1579, 1982
Zatz R, Anderson S, Meyer TW, Dunn BR, Rennke HG, et al. Lowering of arterial blood pressure limits glomerular sclerosis in rats with renal ablation and in experimental diabetes. Kidney International 20: S123–S129, 1987
Zatz R, Meyer TW, Rennke HG, Brenner BM. Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proceedings of the National Academy of the Sciences USA 82: 5963–5967, 1985
Zusman RM. Renin and non-renin mediated antihypertensive actions of converting enzyme inhibitors. Kidney International 25: 969–983, 1984
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
McAreavey, D., Robertson, J.I.S. Angiotensin Converting Enzyme Inhibitors and Moderate Hypertension. Drugs 40, 326–345 (1990). https://doi.org/10.2165/00003495-199040030-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199040030-00002